You think use in such other neurological disorders is covered here?
It should be. What’s not covered by the new Botox approval is treatment for idiopathtic OAB, which is a larger market than the indication that was just approved.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”